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Abstract
Polypeptide growth factors form a potent class of extracellular signal molecules in the regulation of cellular differentiation
and proliferation. Disturbances in the expression of growth factors influence the normal pathway of differentiation and
lead to cellular transformation and tumour progression. Contemporary medical studies report that various growth factors
such as those for platelet-derived growth factor, vascular endothelial growth factor, epidermal growth factor, hepatocyte
growth factor and insulin-like growth factor are expressed in gastroenteropancreatic neuroendocrine tumours (GEP/NET).
Polypeptide growth factors have great significance in the growth, progression and development of metastases by various
tumours. We describe the role of growth factors in GEP/NET on the basis of the available reports of medical research.
(Pol J Endocrinol 2007; (58) 1: 4250)
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Streszczenie
Czynniki wzrostu tworz„ liczn„ klasŒ cz„steczek bior„cych udzia‡ w przekazywaniu sygna‡u zewn„trzkomórkowego,
reguluj„c ró¿nicowanie i wzrost komórek. Zaburzenia w ekspresji czynników wzrostu wp‡ywaj„ na zak‡ócenie prawid‡o-
wej drogi ró¿nicowania komórkowego, prowadz„c do komórkowej transformacji i progresji guza. W najnowszych bada-
niach wykazano, ¿e ró¿ne czynniki wzrostu, takie jak: p‡ytkopochodny czynnik wzrostu, czynnik wzrostu ródb‡onka
naczyæ, nab‡onkowy czynnik wzrostu, czynnik wzrostu hepatocytów i insulinopodobny czynnik wzrostu (IGF, insulin-like
growth factor) wykazuj„ ekspresjŒ w guzach neuroendokrynnych uk‡adu pokarmowego (GEP/NET). Polipeptydowe czyn-
niki wzrostu odgrywaj„ istotne znaczenie w rozwoju i wzrocie przerzutów w ró¿nych typach nowotworów. W niniejszej
pracy opisujemy ich rolŒ w GEP/NET na podstawie dostŒpnej literatury medycznej.
(Endokrynol Pol 2007; (58) 1: 4250)
S‡owa kluczowe: ¿o‡„dkowo-jelitowo trzustkowe guzy neuroendokrynne, czynniki wzrostu, insulinopodobny czynnik wzrostu,
p‡ytkopochodny czynnik wzrostu, czynnik wzrostu ródb‡onka naczyæ, nab‡onkowy czynnik wzrostu, czynnik wzrostu fibroblastów
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Introduction
Gastroenteropancreatic neuroendocrine tumours (GEP/
/NET) are generally considered to be slow-growing neo-
plasms. However, in a significant subset aggressive
growth occurs, resulting in decreased survival [13]. The
aberrant expression of growth factors and/or aberrant
responses to growth factors may circumvent the nor-
mal pathway of differentiation, leading to cellular trans-
formation, tumour progression and maintenance of the
transformed phenotype [4, 5]. The most common mali-
gnant symptomatic pancreatic endocrine tumour (PET)
[6, 7] is a gastrinoma which, in 25% of patients, has an
aggressive growth pattern, leads to the development of
liver metastases and results in a 10-year-survival in 30%
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of patients [8]. At present the factors responsible for the-
se variable growth patterns in different PET as well as
in gastrinomas are largely unknown. This situation exi-
sts because the molecular pathogenesis of NET has not
been sufficiently investigated [9]. Recent studies report
that various growth factors are expressed in gastroente-
ropacreatic neuroendocrine tumors (GEP/NET) (Table I)
and play an important role in the growth, progression
and development of metastases of various tumours
[912]. These growth factors include fibroblast growth
factors (aFGF, bFGF), transforming growth factors
(TGFa, TGFb), an epidermal growth factor (EGF), pla-
telet-derived growth factors (PDGF), insulin-like growth
factors (IGF1, IGF2) hepatocyte growth factor and in-
terleukins (IL-1, IL-2).
Insulin-like growth factor 1 (IGF-1)
IGF-1 is a 70-amino-acid anabolic hormone. In normal
conditions IGF-1 is produced by growth hormone (GH)
in the liver [13]. Insulin-like growth factor receptor
(IGF-1R) is a member of the tyrosine kinase (TK) recep-
tor super-family with a 70% homology to the insulin
receptor [11]. IGF-1R activation can induce numerous
cellular effects, including differentiation, transformation
and prevention of apoptosis. The activation of IGF-1R
increases tumour growth and up-regulates vascular en-
dothelial growth factor expression, promoting tumour
invasion [14, 15]. Activation of IGF-1R causes activation
of at least two signal cascades. The first cascade promo-
tes the survival of cells by the sequential passing of in-
formation by phosphatidylinositol kinase 3 (PI3K), pro-
tein kinase B (PKB), GSF3b, b-katenin and the transcrip-
tive activator regulated by the Myc-TCT 4 protein. In
the cells of a pancreatic tumour the activation of PKB
can cause an up-regulation of expression of IGF-1R and
positive feedback, which extends the survival of cells.
In contrast, the second cascade (the cascade of Ras-Raf-
-MAPK) promotes cellular proliferation. Therefore dif-
ferent cascades activated by IGF-1R in different cellular
arrangements can be partially determined by differen-
ces in the mode of activating them (Fig. 1). A high con-
centration of IGF-1 is recognised as a risk factor for the
appearance of malignant tumours in the prostatic gland,
breast and colon [13], but its expression pattern in the
functionally and biologically heterogeneous human
GEP/NET should be thoroughly elucidated [16]. Cur-
rently there are some reports of IGF-1 and/or IGF-1R as
present in some NET and these are associated with an
advanced tumour stage, increased tumour size, prolife-
rative activity, recurrence or metastases and a poor pro-
gnosis/survival [1721]. In isolated NET IGF-1 can sti-
mulate tumour growth [22]. Other studies have repor-
ted no association between IGF-1/IGF-1R and tumour
stage, size or survival [17, 18, 21, 23, 24]. In two studies
involving different PET [9, 16, 25] and three studies in-
volving GEP/NET [9, 16, 22, 25] the presence or absence
of IGF-1 and/or IGF-1R did not correlate with tumour
aggressiveness. However, no quantitative comparisons
were performed in these studies [9, 16, 22, 25]. Incre-
ased IGF-1R mRNA expression in gastrinoma correla-
ted significantly with increased tumour growth, aggres-
sive disease and increased tumour extent, as, to a lesser
degree, did IGF-1 expression.
Furukawa et al. [26] reported that both IGF-1 and
IGF-1R mRNA expression levels are related to gastrino-
ma aggressiveness and that IGF-1R levels are predicti-
ve of disease-free survival, which could have clinical
significance. The assessment of IGF-1R mRNA levels in
the gastrinoma may allow stratification of patients to
different risk levels, which could be used to determine
risk and allow identification of patients requiring more
careful follow-up. However, in the light of the incre-
ased development of possible therapeutic strategies di-
rected against IGF-1R [10] and the effects of such drugs
as somatostatin analogues in decreasing IGF-1 secretion,
the possible involvement of IGF-1R in the molecular
pathogenesis of these tumours, together with the link
between its expression and tumour aggressiveness, ra-
ises the possibility that an approach directed against
Table I
Localisation of the expression of growth factors from among gastroenteropancreatic neuroendocrine tumours (GEP/NET)
Tabela I
Lokalizacja ekspresji czynników wzrostu wród guzów neuroendokrynnych przewodu pokarmowego
    Localisation Fore- Midgut Hindgut Gastrinoma Insulinoma Functionally Well- PET
-gut NET carcinoid NET inactive -differentiated
Growth tumours in neuroendocrine
factor GEP/NET  tumors
IGF-1 +[44. 77] + [27. 30] + [30] + [30]
VEGF + [69]
EGF and HGF + [46] + [47] +[47]
TGFa + [47] +[46. 47] + [27. 47]
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IGF-1R could have therapeutic value in treatment of
the tumours. In 2004 Van Gompel Chen [27] described
the activation of a raf-1/MEK1 pathway which rever-
sed the effect of IGF-1 treatment by the depletion of
intracellular chromogranin A (CgA). The induction of
the raf-1/MEK1 pathway blocks IGF-1-mediated intra-
cellular neuroendocrine hormone regulation. Therefo-
re raf-1/MEK1 activation may be a viable method for
blocking IGF-1-mediated cellular effects and serve as
a therapeutic target in gastrointestinal carcinoid tumours.
Von Wichert et al. [28] first presented the Ras/PI3K/
/AKT/Rac/NFkappaB/cyclin D1 signalling cascade. Con-
stitutive expression of cyclin D1 is a frequent abnorma-
lity in human cancer and sustains the transformed phe-
notype. They previously demonstrated that cyclin D1
is constitutively expressed in human BON NET cells as
a result of an autocrine IGF-1 loop. Their data provide
the first comprehensive map of the signalling events
elicited by endogenously released IGF-1 leading to con-
stitutive cyclin D1 expression in human NET.
Wulbrand et al. [16] reported a study of IGF system
components, including insulin-like growth factor bin-
ding proteins (IGFBPs), in the European Journal of
Clinical Investigation in 2000. They showed differen-
ces in the expression patterns of the IGF system com-
ponents in NET subtypes, which suggest pathways in
tumour growth control that are differentiated according
to tumour type by means of IGF system components
[16]. IGFBPs are important in the carcinogenesis of se-
veral tumours, but their expression pattern in the func-
tionally and biologically heterogeneous human GEP/
/NET has not been adequately identified [16]. There are
several IGFBPs by which the total serum concentration
of IGF-1 is maintained at a level 1000 times higher than
the concentration of free insulin. Synthesis of IGFBPs,
like that of IGF, depends on GH; both IGF-1 and GH
induce the expression of IGFBPs, while insulin reduces
it. By reducing the biological accessibility of IGF-1, IG-
FBP can modify free GH activity. The isoform of IGFBP
present in blood serum in the largest quantity is IGFBP3.
The enzymes produced by malignant tumours in hu-
mans such as protease serine, the special antigen for
cancer of the prostatic gland, can split the IGFBP (for
example, in metastases), thus enlarging the biological
accessibility of growth factors [13]. Wulbrand et al. [16]
analysed 37 tumour samples (9 gastrinomas, 10 insuli-
nomas, 9 tumours associated with carcinoid syndrome
and 9 functionally inactive tumours), in all of which
IGFBP-2 was found, while IGFBP-1 was expressed only
at a low frequency (1022%) among the four tumour
types. Because expression of IGFBP-2 correlates with
the proliferation of some tumour cell lines and has been
associated with an increased malignancy of certain tu-
mours [2931], IGFBP-2 could facilitate the autocrine
action of IGF-1 and thereby increase its half-life [32].
Another study of IGFBP was published in Clinical
Cancer Research in 2004. In this Donna E. Hansel [33]
described the role of IGFBP3 and MET proto-oncogene
Figure 1. Different cascades activating growth factors in different cellular arrangements. Kinase tyrosine receptors activate Ras-Raf-
-MAP (serine-treonine kinases), PI3K phosphatidylinositol kinase 3, protein kinase C (PKC) and calcium
Rycina 1. Ró¿ne kaskady aktywowane przez czynniki wzrostu w poszczególnych przedzia‡ach komórkowych. Receptory dla kinazy
tyrozynowej aktywuj„ drogŒ Ras-Raf-MAP (kinazy serynowo-treoninowe), PI3K (kinaza fosfatydyloinozytolu 3), PKC (kinaza
bia‡kowa C) i wapnia
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with metastatic ability in well-differentiated pancreatic
endocrine neoplasms. IGFBP3 functions as a carrier
molecule for both IGF-1 and IGF-2 in the circulation [34,
35]. IGFBP3 mediates both pro- and anti-proliferative
effects on various cell types [35]. Increased serum levels
of IGFBP3 have been associated with the progression
of breast cancer in several studies [36, 37]. Overexpres-
sion of IGFBP3 in non-metastatic pancreatic endocrine
neoplasms as opposed to normal human islet cells has
previously been identified [38]. Analysis of IGFBP3
expression in metastatic compared with non-metasta-
tic pancreatic endocrine neoplasms identified IGFBP3
expression in 42% of non-metastatic pancreatic endo-
crine neoplasms and 80% of metastatic primary pancre-
atic endocrine neoplasms. In addition, IGFBP3 expres-
sion was identified in 86% and 100% of lymph node and
liver metastases respectively.
MET functions as a transmembrane receptor of TK
that is activated by hepatocyte growth factor/scatter fac-
tor [39]. Inappropriate expression of MET has been do-
cumented in the majority of solid tumour types and
often appears to correlate with a worsened prognosis
[40]. MET signalling results in disruption of cell-to-cell
adhesion, branching morphogenesis and invasive and
metastatic behaviour by a large array of neoplasms [41].
The expression of MET has been identified in 17% of
non-metastatic pancreatic endocrine neoplasms compa-
red with 33% of primary pancreatic endocrine neopla-
sms demonstrating concurrent metastases. MET expres-
sion appeared most prevalently in lymph node (57%)
and liver (56%) metastases. Like IGFBP3, MET expres-
sion may also demonstrate a continuum of expression
with neoplastic progression [33].
Another problem in medical studies concerns the
autocrine action of IGF-1/IGFR [32, 42]. Exogenously
added IGF-1 induces a marked increase in the secre-
tion of CgA, a marker protein for neuroendocrine se-
cretion, by a process that is largely dependent on
PI3-kinase activity. In addition, immunoneutralisation
of endogenously released IGF-1 markedly reduces the
basic chromogranin secretion level. The constitutive
activation of certain kinases under serum-free condi-
tions is increasingly appreciated as a mechanism leading
to the autonomous growth of tumour cells in culture. It
has been suggested that the PI3-kinase-phosphorylated
products of phosphatidylinositol play a role in the re-
gulation of membrane trafficking along secretory path-
ways, for example in chromaffin cells [43]. Therefore
by targeting either PI3-kinase or endogenously released
IGF-1, both autocrine and neuroendocrine secretory
pathways can be substantially blocked in BON cells.
Targeting IGF-1 or the IGF-1 receptor TK may constitu-
te a novel therapeutic strategy for patients suffering
from NET. Endogenously released IGF-1 is found to be
largely responsible for the autonomous growth of BON
cells in a serum-free medium and for the constitutive
expression of cyclin D1 in these cells. In conclusion, IGF-1
is a major autocrine regulator of neuroendocrine secre-
tion and the growth of human BON NET cells [42].
The epidermal growth factor family
of polypeptide growth factors
Transforming growth factor a (TGFa)
Transforming growth factor a is one of the growth factors
that are similar to epidermal growth factors (EGF) [13].
It is a 50-amino-acid polypeptide that binds to the epi-
dermal growth factor receptor (EGFR) and stimulates
cell growth. It has been suggested that enhanced pro-
duction of TGFa and EGFR by tumour cells promote
tumour-cell growth by autocrine mechanisms [44]. Kri-
shnamurthy and Dayal [45] analysed the expression of
TGFa and EGFR in mid-gut, fore-gut and hind-gut NET
in a study in 1997. They reported that although TGFa is
expressed by a high proportion of these tumours, the
absence of its intact EGFR molecule on the tumour cells
renders it functionally ineffective as a growth factor.
Thus, in contrast to its influence on tumours of the ga-
strointestinal tract, TGFa appears to play no role in the
growth and progression of mid-gut, fore-gut and hind-
gut NET, which perhaps explains the indolent beha-
viour and slow biological progression of GEP/NET.
In another paper Nillson et al. [44] also evaluated
expression of TGFa and EGFR in phaeochromocytomas
and medullary thyroid carcinomas. TGFa expression
was demonstrated in biopsies of all the tumours exami-
ned (n = 30) and EGF receptors in the majority of tu-
mours by Northern analysis and/or immunocytochemi-
stry. Expression of TGFa and EGF receptors was also
demonstrated in primary cultures of tumour cells. The
amount of secreted TGFa could be suppressed by octre-
otide treatment in individual tumours. The growth-sti-
mulatory effect of TGFa could be partially blocked by
the use of neutralising anti-EGF receptor monoclonal
antibodies (MAbs). In conclusion, several human NET
express both TGF-a and EGFR in vivo and in vitro, sug-
gesting that TGFa may regulate tumour-cell growth by
autocrine mechanisms.
Epidermal growth factor (EGF)
Epidermal growth factor is one of the smallest of the
growth factors. It is a 33-amino-acid polypeptide splin-
tered off a large precursor binding to the membrane
[13]. EGF, like all growth factors, binds to specific high-
affinity, low-capacity receptors on the surface of respon-
sive cells. Intrinsic to the EGF receptor is TK activity,
which is activated in response to EGF binding. The ki-
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nase domain of the EGF receptor phosphorylates the
EGF receptor itself (autophosphorylation), as well as
other proteins, in signal transduction cascades that as-
sociate with the receptor following activation. Experi-
mental evidence has shown that the Neu proto-onco-
gene is a homologue of the EGF receptor. EGF has pro-
liferative effects on cells of both mesodermal and ecto-
dermal origin, particularly keratinocytes and fibroblasts.
EGF exhibits negative growth effects on certain carci-
nomas, as well as hair follicle cells. Growth-related re-
sponses to EGF include the induction of nuclear proto-
oncogene expression, such as Fos, Jun and Myc. EGF
also has the effect of decreasing gastric acid secretion
[46]. The expression and activation of growth factor re-
ceptors, particularly for EGF and hepatocyte growth
factor (HGF), in many endocrine and non-endocrine
tumours is important in predicting tumour recurrence,
growth and aggressiveness [4751]. Activation of the
EGFR is reported not only to increase tumour growth
but also to have potent angiogenic effects and promote
tumour invasion, adhesion, and motility [47]. Similarly,
activation of the hepatocyte growth factor receptor
(HGFR) can cause mitogenesis as well as increased mo-
tility and invasiveness [49]. Overexpression of both
EGFR and HGFR in various tumours is associated with
increased tumour size, tumour stage, lymph node me-
tastases and a poor prognosis/survival [48, 5259].
Peghini et al. [60] reported that EGFR and HGFR
mRNA are universally expressed in gastrinomas. Fur-
thermore, each of them is overexpressed in a minority
(1520%) of gastrinomas, and this overexpression cor-
relates with aggressive growth and lower curability.
In another study from the USA Papouchado et al. [61]
analysed the expression of EGFR and activated EGFR
in well-differentiated NET, including primary and me-
tastatic GEP/NET and PET. Their results indicate that
gastrointestinal NET, as well as PET, express EGFR and
activated EGFR, and that this expression is more com-
mon in GEP/NET compared to PET. These findings im-
plicate the EGFR and P-EGFR signal transduction path-
way in the pathogenesis of these NET and suggest that
targeted therapy directed against the EGFR TK domain
may be a useful therapeutic approach in patients with
unresectable metastatic gastrointestinal NET and PET.
Platelet-Derived Growth Factor (PDGF)
Platelet-derived growth factor is composed of two di-
stinct polypeptide chains, A and B, which form homo-
dimers (AA or BB) or heterodimers (AB). The c-Sis pro-
to-oncogene has been shown to be homologous to the
PDGF A chain. Only the dimeric forms of PDGF inte-
ract with the PDGF receptor. Two distinct classes of
PDGF receptor have been cloned, one specific for AA
homodimers and another that binds BB and AB type
dimers. Like the EGF receptor, the PDGF receptors have
intrinsic TK activity. Following autophosphorylation of the
PDGF receptor, numerous signal-transducing proteins
associate with the receptor and are subsequently tyrosine
phosphorylated. Proliferative responses to PDGF action
are exerted on many mesenchymal cell types. Other
growth-related responses to PDGF include cytoskeletal
rearrangement and increased polyphosphoinositol turno-
ver. Again, like EGF, PDGF induces the expression of
a number of nuclear localised proto-oncogenes, such as
Fos, Myc and Jun. The primary effects of TGF-b are due to
the induction, by TGF-b, of PDGF expression [46].
Chaudhry et al. in their 1993 study [62] reported that
multiple peptide growth factors, PDGF, TGF-b, and
bFGF are expressed by GEP/NET. PDGF was expressed
on tumour cells and stroma in 70% of the tissues exami-
ned. PDGF alpha-receptor was seen on clusters of tu-
mour cells and occasionally on adjacent stroma, whe-
reas PDGF beta-receptor was seen only in the stroma.
Their data suggest that PDGF may be involved in the
autocrine stimulation of tumour cells and stimulation
of stromal cell growth through a paracrine and possibly
an autocrine mechanism.
Vascular Endothelial Growth Factor (VEGF)
Vascular endolethial growth factor (also known as
VEGF-A, but commonly referred to simply as VEGF)
stimulates vascular endothelial cell growth, survival,
and proliferation. It plays a significant role in the deve-
lopment of new blood vessels (angiogenesis) and the
survival of immature blood vessels (vascular maintenan-
ce). VEGF binds to and activates two related receptors
found on the endothelial cell membrane. These are
known as VEGF receptor-1 (VEGFR-1 or flt-1) and
VEGFR-2 (KDR or flk-1) and are expressed by endothe-
lial cells within the blood vessel wall. VEGF also inte-
racts with the structurally distinct receptors neuropilin
(NP)-1 and NP-2 (which are normally expressed on
endothelial cells and enhance the mitogenic effects of
VEGFR-2). The binding of VEGF to these receptors ini-
tiates a signalling cascade that affects the survival, pro-
liferation, and migration of endothelial cells, ultimately
leading to angiogenesis [63, 64]. VEGF expression/ove-
rexpression has been shown to be a key mediator of
angiogenesis across multiple tumour types, including
colorectal, lung, breast and other cancers. Across each
of these cancers a number of interrelated signals and
processes have been identified as leading to the pro-
duction of VEGF and, ultimately, the neovascularisa-
tion of a tumour [65].
In 2003 la Rosa et al. [66] reported expression of
VEGF and its receptors did not correlate with micro-
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vessel density or malignancy. These results suggest that
in normal tissues endothelial functions may be regula-
ted by VEGF produced by some endocrine cells and that
a VEGF/VEGFR binding mechanism may be involved
in tumourigenesis but not in tumour progression and
aggressiveness.
In another paper Terris [67] demonstrated that neu-
roendocrine cells are a major source of VEGF, particular-
ly in carcinoids. This finding suggests that the presence
of VEGF may be required to maintain the differentiated
state of capillary vessels in these hypervascular tumo-
urs. Such secretion, in conjunction with the other growth
factors synthesised by these NET, may have an impor-
tant role in tumour growth. No correlation between
VEGF expression and tumour stage was found.
Neuropilin-2 (NP-2)
Neuropilin-2 (NP-2) is a cell surface transmembrane
protein originally characterised as a receptor for type 3
semaphorins and, more recently, for a number of va-
scular endothelial growth factor (VEGF) isoforms [68].
Cohen et al. [68] analysed the expression of NP-2 in pan-
creatic islet cells and PET as a novel marker. NP-2 expres-
sion has recently been localised to a subset of neuroendo-
crine cells in the gastrointestinal tract. NP-2 expression was
not detected in neuroendocrine cells outside the gastroen-
teropancreatic system or in their corresponding neoplasms,
except for focal staining in one bronchial carcinoid tumour.
In conclusion, the vast majority of PET examined expres-
sed NP-2, suggesting its utility as a diagnostic marker for
these tumours. The function of NP-2 in islet cell biology or
tumourigenesis remains to be elucidated.
Fibroblast Growth Factors (FGFs)
Endocrine tumours (ETs) of the digestive system pro-
duce several growth factors, including acidic and basic
(aFGF and bFGF respectively), which are thought to be
involved in the growth of tumour cells and in the proli-
feration of tumour stromal cells.
La Rosa et al. [69] described the immunohistoche-
mical detection of FGF receptors in normal endocrine
cells and related tumours of the digestive system. Ente-
rochromaffin cell (EC) tumours, which were all positi-
ve for aFGF, were found to express at least three diffe-
rent fibroblast growth factor receptors (FGFRs). FGFRs
were also localised in the stromal cells of all the tumo-
urs examined. The tumour stroma was more abundant
in EC cell tumours than in other types of neoplasm. The
results suggest that aFGF-FGFR interaction may be in-
volved in the modulation of normal endocrine cell func-
tions and in the regulation of tumour growth and stro-
mal proliferation of EC cell tumours.
Treatment of GEP/NET
The treatment of choice for GEP/NET is surgery. Sur-
gery should be considered in cases with liver metasta-
ses and potentially resectable tumour. For patients who
are not fit for surgery the aim of treatment is to impro-
ve and maintain an optimal quality of life. The choice
of treatment depends on the symptoms, stage of dise-
ase, degree of radionuclide uptake and histological fe-
atures of the tumour. Treatment choices for non-resec-
table disease include somatostatin analogues, biothera-
py, chemotherapy, radionuclides and ablation therapies
[70]. The anti-neoplastic therapy of advanced NET is
still unsatisfactory and innovative therapeutic appro-
aches are needed [71].
At present intensive research is being conducted on
new drugs, including inhibitors of growth factors. This
therapy could turn out to be indispensable in the futu-
re because of the great role played by growth factors in
the development and pathogenesis of GEP/NET. Apart
from the IGF-1R TK inhibitor described, different inhi-
bitors of growth factors are enumerated in the literatu-
re, although the investigations do not concern GEP-
-NET. The medications include:
 AEE788, a dual family epidermal growth factor re-
ceptor/ErbB2 and vascular endothelial growth fac-
tor receptor TK inhibitor with an anti-tumour and
anti-angiogenic action (cell lung cancer, glioblasto-
mas, and breast tumours) [72];
 SU6668, a potent anti-angiogenic and anti-tumour
agent that induces regression of established tumo-
urs (glioma and melanoma of lung, colon, ovarian,
and epidermoid origin) [71];
 SU11248, a novel TK inhibitor targeting VEGF and
PDGF receptors [73].
The inhibition of the IGF/IGF-receptor system may
offer possibilities for novel targeted treatment strate-
gies of NET because these frequently express insulin-
like growth factors and their receptors, which are
known to promote survival, oncogenic transformation,
tumour growth and spreading [74].
Hopfner et al. [74] described the anti-neoplastic ef-
fects of the inhibition of IGF-1R signalling in NET cells
by the novel IGF-1R-TK inhibitor NVP-AEW541, who-
se anti-neoplastic potency has not yet been tested in
NET disease. Apoptosis was characterised by activation
of the apoptotic key enzyme, caspase-3, as well as by
detection of changes in the expression of the pro- and
anti-apoptotic proteins, BAX and Bcl-2, after NVP-
-AEW541 treatment. The cell cycle was arrested at the
G1/S checkpoint. The anti-neoplastic effects of NVP-
-AEW541 involved the inactivation of ERK1/2. The in-
duction of immediate cytotoxicity did not account for
the anti-neoplastic effects of NVP-AEW541, as shown
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by measurement of lactate dehydrogenase release.
Moreover, additive anti-neoplastic effects were obse-
rved when NVP-AEW541 was combined with cytosta-
tics such as doxorubicin or the 3-hydroxy-3-methylglu-
taryl coenzyme A reductase inhibitor, fluvastatin. This
is the first report on the induction of apoptosis and cell
cycle arrest by the IGF-1R-TK inhibitor NVP-AEW541
in NET cells. The inhibition of the IGF-1/IGF-1R system
appears to be a promising novel approach for future
treatment strategies of GEP/NET.
There is a need for more extensive research into tu-
mour biology, including that concerned with the roles
of growth factors. A better understanding of the mole-
cular biology of these tumours may lead to better clini-
cal models for predicting outcome and developing no-
vel treatment strategies for this relatively rare but com-
plex disease.
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